Innovent Biologics Inc. and HUTCHMED (China) Limited (HCM) announced that the New Drug Application for the combination of TYVYT (sintilimab injection) and ELUNATE (fruquintinib) has received conditional approval in China. This approval is for the treatment of patients with advanced endometrial cancer who have Mismatch Repair proficient (pMMR) tumors, have failed previous systemic therapies, and are not candidates for curative surgery or radiation.
The approval follows the priority review status and breakthrough therapy designation by the National Medical Products Administration (NMPA) of China and marks the eighth approved indication for TYVYT (sintilimab injection).
The conditional approval by the NMPA was supported by registration stage data from FRUSICA-1, the endometrial cancer registration cohort of a multi-center, open-label Phase 2 study investigating sintilimab in combination with fruquintinib in endometrial cancer patients who have experienced disease recurrence, disease progression or intolerable toxicity with treatment on platinum-based doublet chemotherapy.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.